How to appeal a Humana prostate cancer denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for prostate cancer

Cited policy: Humana Provenge (Sipuleucel-T) Coverage for Asymptomatic/Minimally-Symptomatic mCRPC

Asymptomatic OR minimally-symptomatic mCRPC. ECOG 0-1. No visceral metastases. Castrate testosterone <50 ng/dL on ongoing ADT. No active autoimmune disease, no concurrent immunosuppression. 3 IV infusions q2wk of autologous antigen-presenting cells loaded with PA2024 (PAP-GM-CSF). CMS NCD 110.22 covers within FDA labeling.

How Humana denies prostate cancer — and how to counter it

Where Humana pushes back: 1) Provenge 'experimental' or 'investigational'; 2) Insufficient survival benefit to justify cost; 3) Should use Pluvicto / ARSI escalation instead.

Counter-arguments that hold up: FDA-approved Apr 29, 2010 — Provenge is the FIRST FDA-approved cancer immunotherapy and is NOT experimental. IMPACT NEJM 2010 Kantoff — OS HR 0.78, 4.1-mo median OS benefit (25.8 vs 21.7 mo) and 38% reduction in death risk over 3 years. NCCN Prostate v1.2025 Category 1 for asymptomatic/minimally-symptomatic mCRPC. AUA Advanced Prostate 2023 endorses. CMS NCD 110.22 covers Medicare. Provenge is COMPLEMENTARY to ARSI/PARPi/Pluvicto (different mechanism — autologous DC vaccine vs AR-pathway / DNA-repair / radioligand) — sequencing supported by NCCN. Cost-effectiveness studies (ICER 2018) within accepted oncology thresholds.

What Humana typically denies for prostate cancer

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For prostate cancer, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the prostate cancer treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Pluvicto (177Lu-PSMA-617)
• Xofigo (radium-223)
• Xtandi (enzalutamide)
• Erleada (apalutamide)
• Nubeqa (darolutamide)
• Zytiga (abiraterone)

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.